Aptar Pharma completes initial stage of global injectables expansion project

US – Aptar Pharma, a global leader in drug delivery systems, services, and active material science solutions, has completed the first stage of its US$180 million injection system solutions expansion program.

The multisite, international expansion project began in 2020 and is intended to significantly boost capacity across all product lines, ultimately enabling Aptar Pharma to produce over 10 billion injectable component units annually when completed.

Aptar Pharma President Gael Touya said: “Our planned expansion program proved timely and was expedited by the arrival of the Covid-19 pandemic.

“The investments we’re making to expand manufacturing capacity and in new, digitalized processes will benefit our customers well into the future.”

The investment will be used to increase the production of vial stoppers, elastomer components, PremiumFill improved specification solutions, and PremiumCoat ETFE film-coated components around the world.

The program involves investments in France and the US, increasing the production footprint by more than 23,000m², Aptar said.

The initial phase of the PremiumCoat capacity expansion is already operational in Granville, France and features new ISO7 clean rooms and advanced robotics.

The company says a new factory using advanced technologies will be operating in Granville, France by early 2024.

Aptar Pharma said that the US-based manufacturing capabilities will also be operational by 2024 to better serve the local market. The program also includes additional phases of production expansion in the US and France.

According to the firm, the opening of a second facility in Granville, France, represents a new turning point in its transition and sets the way for an increase in capacity and high-tech effectiveness.

The company also received a portion of €13m French government’s Program of Investments for the Future to construct and expand its European facilities.

The advanced automated factory will boost manufacturing capacity and help fulfill the demand for elastomeric components, including PremiumCoat solutions for improved drug/container compatibility.

To meet the ever-increasing market and customer requirements for even higher quality and reliability, Aptar Pharma is expanding its capabilities with robotization, digitalization and new clean rooms.

Sustainability is a major consideration in Aptar Pharma’s expansion program, with the implementation of solar power production, water waste management and optimized energy consumption included.

For all the latest packaging and printing industry news from Africa and the World, subscribe to our NEWSLETTER, follow us on Twitter and LinkedIn, like us on Facebook, and subscribe to our YouTube channel.

Related posts

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.